The value of personalizing medicine: Medical oncologists’ and patients’ perspectives on genomic testing of breast tumors in chemotherapy treatment decisions.

e11000 Background: Benefits of adjuvant chemotherapy for early-stage breast cancer patients (pts) depend on baseline recurrence risks. Gene expression profiling (GEP) of tumours informs baseline risk prediction, potentially reducing unnecessary treatment and healthcare costs. Limited evidence exists on its clinical utility; we explored pts and medical oncologists (MO) perspectives on GEP in chemotherapy decisions. Methods: We …